查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
抗凝劑的全球市場 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1149307

抗凝劑的全球市場 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

Anticoagulant Reversal Drugs Market (Product: Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 153 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球抗凝劑市場相關調查分析，提供市場動態，市場區隔分析，地區分析，企業簡介等資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球抗凝劑市場

第4章 市場概要

  • 簡介
    • 意義
    • 產業的演進/發展
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球抗凝劑市場分析與預測(2017年～2031年)

第5章 主要考察

  • 主要的產業的發展(合併和收購，產品的銷售，夥伴關係)
  • 開發平台分析
  • 償付情景:各地區/世界
  • 法規情景:各地區/世界
  • COVID-19疫情對產業影響

第6章 全球抗凝劑市場分析與預測:各產品

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各產品(2017年～2031年)
    • 凝血素原複合體濃縮物
    • 維他命K
    • 魚精蛋白
    • 傳明酸
    • 伊達賽珠單抗
    • AndeXXa
    • 其他
  • 市場魅力分析:各產品

第7章 全球抗凝劑市場分析與預測:各流通管道

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各流通管道(2017年～2031年)
    • 醫院藥局
    • 零售藥局
    • 其他
  • 市場魅力分析:各流通管道

第8章 全球抗凝劑市場分析與預測:各地區

  • 主要調查結果
  • 市場金額的預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各地區

第9章 北美的抗凝劑市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場金額的預測:各產品(2017年～2031年)
  • 市場金額的預測:各流通管道(2017年～2031年)
  • 市場金額的預測:各國(2017年～2031年)
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各產品
    • 各流通管道
    • 各國

第10章 歐洲的抗凝劑市場分析與預測

第11章 亞太地區的抗凝劑市場分析與預測

第12章 南美的抗凝劑市場分析與預測

第13章 中東·非洲的抗凝劑市場分析與預測

第14章 競爭情形

  • 市場企業 - 競爭矩陣:階層·不同企業規模
  • 市場佔有率分析:各企業(2021年)
  • 企業簡介
    • Amneal Pharmaceuticals, Inc.
    • Bausch Health Companies, Inc.
    • Boehringer Ingelheim GmbH
    • CSL Limited
    • Fresenius Kabi AG
    • Perosphere Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Portola Pharmaceuticals, Inc.
    • Octapharma AG
Product Code: TMRGL40970

The report provides revenue of the global anticoagulant reversal drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anticoagulant reversal drugs market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anticoagulant reversal drugs market.

The report delves into the competitive landscape of the global anticoagulant reversal drugs market. Key players operating in the global anticoagulant reversal drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anticoagulant reversal drugs market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticoagulant Reversal Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Key Industry Developments (mergers & acquisitions, product launches, partnerships)
  • 5.2. Pipeline Analysis
  • 5.3. Reimbursement Scenario by Region/globally
  • 5.4. Regulatory Scenario by Region/Globally
  • 5.5. Covid-19 Pandemic Impact on the Industry

6. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Product, 2017-2031
    • 6.3.1. Prothrombin Complex Concentrates
    • 6.3.2. Vitamin K
    • 6.3.3. Protamine
    • 6.3.4. Tranexamic Acid
    • 6.3.5. Idarucizumab
    • 6.3.6. AndeXXa
    • 6.3.7. Others
  • 6.4. Market Attractiveness Analysis, by Product

7. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Anticoagulant Reversal Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Product, 2017-2031
    • 9.2.1. Prothrombin Complex Concentrates
    • 9.2.2. Vitamin K
    • 9.2.3. Protamine
    • 9.2.4. Tranexamic Acid
    • 9.2.5. Idarucizumab
    • 9.2.6. AndeXXa
    • 9.2.7. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Others
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Product
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Anticoagulant Reversal Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product, 2017-2031
    • 10.2.1. Prothrombin Complex Concentrates
    • 10.2.2. Vitamin K
    • 10.2.3. Protamine
    • 10.2.4. Tranexamic Acid
    • 10.2.5. Idarucizumab
    • 10.2.6. AndeXXa
    • 10.2.7. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Product
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product, 2017-2031
    • 11.2.1. Prothrombin Complex Concentrates
    • 11.2.2. Vitamin K
    • 11.2.3. Protamine
    • 11.2.4. Tranexamic Acid
    • 11.2.5. Idarucizumab
    • 11.2.6. AndeXXa
    • 11.2.7. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Product
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Anticoagulant Reversal Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product, 2017-2031
    • 12.2.1. Prothrombin Complex Concentrates
    • 12.2.2. Vitamin K
    • 12.2.3. Protamine
    • 12.2.4. Tranexamic Acid
    • 12.2.5. Idarucizumab
    • 12.2.6. AndeXXa
    • 12.2.7. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Product
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product, 2017-2031
    • 13.2.1. Prothrombin Complex Concentrates
    • 13.2.2. Vitamin K
    • 13.2.3. Protamine
    • 13.2.4. Tranexamic Acid
    • 13.2.5. Idarucizumab
    • 13.2.6. AndeXXa
    • 13.2.7. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Product
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share Analysis By Company (2021)
  • 14.3. Company Profiles
    • 14.3.1. Amneal Pharmaceuticals, Inc.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Bausch Health Companies, Inc.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Boehringer Ingelheim GmbH
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. CSL Limited
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Fresenius Kabi AG
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Perosphere Pharmaceuticals, Inc.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Pfizer, Inc.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Portola Pharmaceuticals, Inc.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Octapharma AG
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
  • Table 02: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017-2031
  • Table 05: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
  • Table 06: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 07: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 08: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
  • Table 09: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 10: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
  • Table 12: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
  • Table 15: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
  • Table 18: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Distribution, by Geography, 2021-2031
  • Figure 02: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Forecast, 2022-2031
  • Figure 03: Global Anticoagulant Reversal Drugs Market Value Share, by Product, 2021
  • Figure 04: Global Anticoagulant Reversal Drugs Market Value Share, by Distribution Channel, 2021
  • Figure 05: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2021
  • Figure 06: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
  • Figure 07: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Prothrombin Complex Concentrates (PCC) 2017-2031
  • Figure 08: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Vitamin K, 2017-2031
  • Figure 09: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Protamine, 2017-2031
  • Figure 10: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Tranexamic Acid, 2017-2031
  • Figure 11: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 12: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Idarucizumab, 2017-2031
  • Figure 13: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by AndeXXa, 2017-2031
  • Figure 14: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 15: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
  • Figure 16: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 17: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031
  • Figure 18: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031
  • Figure 19: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%),
  • Figure 20: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2021-2031
  • Figure 21: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 22: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 23: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country, 2021-2031
  • Figure 24: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country, 2022-20316
  • Figure 25: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
  • Figure 26: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 27: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
  • Figure 28: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 32: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 33: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2021-2031
  • Figure 34: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-20316
  • Figure 35: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
  • Figure 36: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 37: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
  • Figure 38: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 39: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 40: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2021-2031
  • Figure 41: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 42: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
  • Figure 43: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 44: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
  • Figure 45: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 46: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 47: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2021-2031
  • Figure 48: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 49: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
  • Figure 50: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 51: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
  • Figure 52: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 53: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 54: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2021-2031
  • Figure 55: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 56: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
  • Figure 57: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
  • Figure 58: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
  • Figure 59: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Global Anticoagulant Reversal Drugs Market Share Analysis, by Company (2021)